Research programme: botanical drug candidates - Phytomedics
Alternative Names: PMI-004; PMI-006; PMI-007; PMI-008; PMI-016Latest Information Update: 16 Jul 2016
At a glance
- Originator Phytomedics
- Class
- Mechanism of Action Cyclo-oxygenase 2 inhibitors; Insulin receptor agonists; Lipoprotein modulators; Protein synthesis stimulants; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Diabetes mellitus; Inflammation; Obesity; Sarcopenia
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Diabetes-mellitus in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Obesity in USA